Hester Biosciences Reports Q1 FY27 Results; Standalone Profit Rises 88% While Consolidated PAT Jumps on Exceptional Gain
Hester Biosciences Limited announced its unaudited financial results for the first quarter of the fiscal year 2027 (Q1 FY27), highlighting strong profitability growth in the standalone business and a significant surge in consolidated profit driven by an exceptional gain.The Company’s financial performance across the divisions showed varying trends, with the Poultry Healthcare division reporting robust growth, while the Animal Healthcare division noted challenges related to government programme scheduling.
Standalone Financial Performance
The standalone results reflected strong operational execution and favourable product mix. Revenue from operations increased by 14%, reaching 726.60 INR Million compared to 634.90 INR Million in the corresponding quarter of FY26.Standalone profitability saw substantial improvement. The Gross Profit Margin improved to 78% from 69%, while PAT (Profit After Tax) increased by 88%, reaching 147.11 INR Million, up from 78.38 INR Million in the previous year's quarter.
The standalone financial highlights are detailed below:
| Metric | Q1 FY27 | Q1 FY26 | Change % |
|---|---|---|---|
| Revenue from Operations (INR Million) | 726.60 | 634.90 | 14% |
| Gross Profit Margin | 78% | 69% | 9% |
| PAT (INR Million) | 147.11 | 78.38 | 88% |
Consolidated Results and Divisional Analysis
In the consolidated results, while revenue from operations declined by 8%, reaching 772.44 INR Million from 841.05 INR Million in FY26, consolidated profitability soared due to a major financial event related to international operations.The exceptional accounting gain of INR 853.49 million was recorded during the quarter. This gain arose from the amendment of the Gates Foundation loan at Hester Africa. Under this agreement, the outstanding loan amount, previously USD 12.0 million, was reduced to USD 5.0 million. Additionally, accrued interest was waived and the revised loan status is interest-free.
Consolidated PAT increased by 459%, reaching 967.32 INR Million from 172.96 INR Million in FY26.
| Consolidated Metric | Q1 FY27 | Q1 FY26 | Change % |
|---|---|---|---|
| Revenue from Operations (INR Million) | 772.44 | 841.05 | -8% |
| Gross Profit Margin | 78% | 73% | 5% |
| PAT (INR Million) | 967.32 | 172.96 | 459% |
Consolidated revenues were lower compared to the previous quarter, primarily due to reduced revenues from operations in Nepal and Africa. The business in Nepal continues to face variability related to institutional order timing and local market conditions, while the Africa business focuses on strengthening registrations, expanding market development activities, and building long-term commercial opportunities across the continent.
Divisional Deep Dive
Poultry Healthcare Division:The Poultry Healthcare Division delivered strong growth, with revenues increasing by 48% over the corresponding quarter of the previous year. This growth was attributed to higher institutional business, deeper market penetration, and continuous strengthening of customer engagement. The division also saw encouraging traction from new health products launched in FY26, including feed supplements and disinfectant solutions, which complement vaccine offerings and contribute to integrated disease prevention and farm health management.
Animal Healthcare Division:
The Animal Healthcare Division faced challenges primarily linked to the timing of government-led immunisation programmes, specifically delays in tender execution. Despite this, the company expressed confidence regarding long-term growth opportunities in preventive animal healthcare and continues efforts to strengthen its portfolio across commercial and institutional markets.
Strategic Focus for FY27
Hester Biosciences Limited reaffirmed its commitment to building long-term competitive advantages through scientific innovation and disciplined execution. The focus areas for the company during FY27 include:- Strengthening the biologicals portfolio across Poultry and Animal Healthcare divisions.
- Expanding market penetration in both domestic and export markets.
- Advancing Research and Development through continued investments in new products and regulatory submissions.
- Improving manufacturing efficiency and enhancing utilization of recently commissioned facilities.
HESTERBIO Stock Price Movement
Shares of Hester Biosciences Limited are rising to ₹2622.6 as of 11:48 AM, gaining 5.03% in live trading amid strong buying momentum. The rally is underpinned by high investor interest, with the stock pushing toward its yearly peak while recording a traded volume of 213,483 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.